Itrakonazola

Itrakonazola
Data klinikal
Nama dagang	Sporanox, Sporaz, Orungal, lain-lain
Nama lain	ITZ
AHFS/Drugs.com	Monograph
MedlinePlus	a692049
Data lesen	AS DailyMed: Itraconazole;
Kategori; kehamilan	AU: B3; ;
Kaedah; pemberian	Mulut (kapsul, larutan), setempat (faraj), intravena (IV)
Kod ATC	J02AC02 (WHO) ;
Status perundangan
Status perundangan	AU: S4 (Preskripsi sahaja) ; KA: Rx sahaja ; UK: POM (Preskripsi sahaja) ; AS: Rx sahaja ;
Data farmakokinetik
Bioketersediaan	~55%, maksimum jika dengan makan
Pengikatan protein	99.8%
Metabolisme	Meluas di hati (CYP3A4)
Metabolit	Hidroksiitrakonazola, ketoitrakonazola,; N-desalkilitrakonazola
Penyingkiran separuh hayat	21 jam
Perkumuhan	Air kencing (35%), tahi (54%)
Pengecam
	Nama IUPAC (±)-1-[(RS)-sec-butyl]-4-[p-[4-[p-[[(2R,4S)-rel-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ2-1,2,4-triazolin-5-one;
Nombor CAS	84625-61-6 ;
PubChem CID	55283;
DrugBank	DB01167 ;
ChemSpider	49927 ;
UNII	304NUG5GF4;
KEGG	D00350 ;
ChEBI	CHEBI:6076 ;
ChEMBL	ChEMBL22587 ;
CompTox Dashboard (EPA)	DTXSID3023180 ;
ECHA InfoCard	100.123.596
Data kimia dan fizikal
Formula	C35H38Cl2N8O4
Jisim molar	705.64
Model 3D (JSmol)	Gambar interaktif;
Kekiralan	Campuran rasem
Takat lebur	165 °C (329 °F)
Keterlarutan dalam air	7.8 ± 0.4 × 10−6 mol/L (pH 1.6) mg/mL (20 °C)
	SMILES O=C1N(/N=C\N1c2ccc(cc2)N7CCN(c6ccc(OC[C@@H]3O[C@](OC3)(c4ccc(Cl)cc4Cl)Cn5ncnc5)cc6)CC7)C(C)CC;
	InChI InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1 ; Key:VHVPQPYKVGDNFY-ZPGVKDDISA-N ;
	(verify)

Itrakonazol (R51211), dicipta pada 1984, ialah agen antikulat triazola dipreskripsi kepada pesakit dengan jangkitan kulat. Ubat ini boleh diberikan melalui mulut atau melalui intravena.

Lihat juga

Rujukan

^ ^a ^b "Itraconazole Use During Pregnancy". Drugs.com. 20 March 2019. Dicapai pada 15 May 2020.
^ "Sporanox 10 mg/mL Oral Solution - Summary of Product Characteristics (SmPC)". (emc). 1 February 2018. Dicapai pada 15 May 2020.
^ Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE (October 2004). "Role of itraconazole metabolites in CYP3A4 inhibition". Drug Metabolism and Disposition. 32 (10): 1121–1131. doi:10.1124/dmd.104.000315. PMID 15242978. S2CID 6941636.
^ "Sporanox (itraconazole) Capsules. Full Prescribing Information" (PDF). Janssen Pharmaceuticals, Inc. Diarkibkan daripada yang asal (PDF) pada 17 May 2018. Dicapai pada 28 August 2016.
^ ^a ^b Vasilev NA, Surov AO, Voronin AP, Drozd KV, Perlovich GL (April 2021). "Novel cocrystals of itraconazole: Insights from phase diagrams, formation thermodynamics and solubility". International Journal of Pharmaceutics. 599: 120441. doi:10.1016/j.ijpharm.2021.120441. PMID 33675927. S2CID 232135660.

Pautan luar

Maklumat farmokologi umum tentang itrakonazol, Institut Kesihatan Negara
Laluan Mulut Itrakonazol, Mayo Clinic

[Drugs.com_pregnancy-1] "Itraconazole Use During Pregnancy". Drugs.com. 20 March 2019. Dicapai pada 15 May 2020.

[2] "Sporanox 10 mg/mL Oral Solution - Summary of Product Characteristics (SmPC)". (emc). 1 February 2018. Dicapai pada 15 May 2020.

[3] Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE (October 2004). "Role of itraconazole metabolites in CYP3A4 inhibition". Drug Metabolism and Disposition. 32 (10): 1121–1131. doi:10.1124/dmd.104.000315. PMID 15242978. S2CID 6941636.

[Sporanox_PI-4] "Sporanox (itraconazole) Capsules. Full Prescribing Information" (PDF). Janssen Pharmaceuticals, Inc. Diarkibkan daripada yang asal (PDF) pada 17 May 2018. Dicapai pada 28 August 2016.

[NikitaVas-5] Vasilev NA, Surov AO, Voronin AP, Drozd KV, Perlovich GL (April 2021). "Novel cocrystals of itraconazole: Insights from phase diagrams, formation thermodynamics and solubility". International Journal of Pharmaceutics. 599: 120441. doi:10.1016/j.ijpharm.2021.120441. PMID 33675927. S2CID 232135660.

[1]

[2]

[3]

[4]

[5]